HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT00592683

Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolarity in Children and Adolescents

Medication studyAges 6–17United States
The study in practice

Understand this study

Who could participate?

This study is for people with bipolarity. Listed age limits: 6 years to 17 years. Other eligibility criteria apply.

Listed locations
CambridgeSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateDecember 2007
Recruitment status
Terminated
Enrollment listed in the registry
20
Sponsor
Massachusetts General Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Dietary supplement, Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 6 Years to 17 Years
Official registry ID
NCT00592683
Official title
Show the full official title

A Randomized Placebo Controlled Clinical Trial of Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents Ages 6-17 With Bipolar Spectrum Disorder

Recruitment & locations

Terminated

Cambridge

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Aripiprazole and Placebo.

Who can participate?

This study is for people with bipolarity. Listed age limits: 6 years to 17 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies